The current pharmacological agents with strong evidences to control CKD are renin–angiotensin–aldosterone-system inhibitors and sodium glucose cotransporter 2 inhibitors (SGLT2i, but individual variability in drug responses and residual risk of CKD needs to be solved. Here, SLC5A2 is linked to chronic kidney disease.